Stifel raises target for Incyte stock to USD 157

Published on 10/07/2026 at 01:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 37.70 percent to USD 1.67 billion. Incyte stock had a EUR 100.11 prior close on October 5, 2026.

Aquarellmalerei des Wilmington Stadtbilds mit modernem Forschungscampus — Incyte Hauptquartier Wilmington Delaware als stimmungsvolles Aquarell am Fluss, Referenz ISIN US45337C1027, Illustration mit AI erstellt.

Incyte (ISIN US45337C1027) had a EUR 100.11 prior close at Lang & Schwarz on October 5, 2026. MarketBeat reported on October 5, 2026 that Stifel raised its Incyte target from USD 145.00 to USD 157.00 and reaffirmed a Buy rating.

Stifel lifts target to USD 157

The target increase gives the latest analyst action a clear numerical anchor, but the cited rating remains Buy rather than a new company forecast. MarketBeat also reported that Stifel's target implied 36.17 percent upside against the USD 115.30 share price cited in its report.

That analyst view followed Incyte's second-quarter report. The target change therefore sits alongside operating evidence, rather than relying only on a chart move.

Revenue growth meets a one-time boost

Incyte's second-quarter 2026 revenue rose 37.70 percent year over year to USD 1.67 billion, while GAAP net income increased 44.60 percent to USD 585.60 million, according to Financial Report Insights on September 25, 2026.

The quality of that growth matters. The same Q2 2026 analysis identified a USD 246.00 million one-time Opzelura Medicaid-rebate reversal, while underlying net sales increased 17.00 percent. That comparison separates reported expansion from the recurring commercial trend.

Nasdaq range frames the valuation

Incyte's market capitalization was USD 22.9 billion on October 6, 2026. Its Nasdaq 52-week range was USD 82.82 to USD 132.60, placing the analyst target above the stated yearly high and making pipeline execution central to the valuation debate.

The company operates across hematology, oncology, inflammation and autoimmunity. The Q2 2026 analysis said Jakafi net sales rose 6.90 percent to USD 816.70 million, while newer products and Opzelura broadened the revenue base ahead of the 2028 Jakafi patent expiries.

Prior close and investor reference

The Lang & Schwarz prior close was EUR 100.11 on October 5, 2026. The euro reference cannot be combined with the Nasdaq dollar range or the Stifel dollar target, so each figure remains tied to its own venue and currency.

The further course of trading is shown by the continuously updated real-time quote of Incyte stock.